

2019 INNOVATION Huvards

DECEMBER 5, 2019

UTHSC Student Alumni Dining Hall

11:00 AM - 1:00 PM

Where Discovery and Opportunity Connect



The University of Tennessee Research Foundation is proud to recognize UT researchers whose innovations better society.

Welcome	Richard Magid, PhD Vice President, UTRF
Chancellor's Message	Steve J. Schwab, MD Chancellor, UTHSC
Spotlight Presenter	Tao Lowe, PhD Associate Professor, College of Pharmacy, Department of Pharmaceutical Sciences, UTHSC
Spotlight Presenter	Denis DiAngelo, PhD Professor, College of Medicine, Department of Orthopaedic Surgery, UTHSC
Innovation Award Recognition	Richard Magid, PhD &
2020 Maturation Grants	Lakita Cavin, JD, PhD Vice President & Senior Staff
Startup Awards Issued Patents	Attorney, UTRF
Special Recognition	Richard Magid, PhD UTRF Vice President
Keynote Address	Duane D. Miller, PhD Professor Emeritus, College of Pharmacy, Department of Pharmaceutical Sciences, UTHSC
Closing Remarks.	Stacey S. Patterson, PhD President, UTRF

2020 Maturation Grants 🚯

Michio Kurosu	In Vivo Evaluation of a Novel DPAGT1 Inhibitor, APPB, Using Patient-Derived Xenograft Models UTHSC College of Pharmacy, Department of Pharmaceutical Sciences
Frank Park	Cannabinoids and Kidney Injury UTHSC College of Pharmacy, Department of Pharmaceutical Sciences
Jonathan Spagnoli,	An Ultrasoundable Extracorporeal Life

An Ultrasoundable Extracorporeal Life Support Training Solution for Team Practices

UTHSC College of Medicine, Department of Pediatric Surgery UTHSC – Simulation Center – CHIPS

Ryan Meacham, Jake Morris, Joseph Abou-Rahma, & Jake Spurlock

Licensed Technologies

L. Darryl Quarles, Zhousheng Xiao, & Charles Ryan Yates

Jarrod Young, & Tim Jancelewicz

Monica Jablonski & Mohamed Moustafa

Kristen Archbold

Bob Moore & Suni Moore

Duane Miller, Charles Ryan Yates, & Frank Park Novel FGF-23 Antagonist Determined by Virtual High-Throughput Screening

Licensee: Inozyme Pharma, Inc.

Microemulsions for Topical Delivery of Water Soluble Drugs Licensee: OculoTherapy, LLC

Maskless, Orally Retained, CPAP System with Nasal Pillows Licensee: Azimuth Sleep Solutions, Inc.

Gem-Trifluoromethyl Analogs of SMM-295 Licensee: Applied Biopharma, LLC

New Paxillin Inhibitors for Treatment of Polycystic Kidney Disease Licensee: Ipax Pharmaceuticals, LLC

Life Pen

UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Spotlight Presenters

Dr. Tao Lowe is currently an Associate Professor of Pharmaceutical Sciences and Biomedical Engineering at UTHSC. Previously, she was an Associate Professor of Pharmaceutical Sciences at Thomas Jefferson University, as well as an Assistant Professor of Surgery, Bioengineering, and Materials Science and Engineering, and Co-Director of the Integrated Graduate Degree Molecular Toxicology Program at Pennsylvania State University. She received her PhD with an Eximia Cum Laude from the University of Helsinki, Finland. She conducted two years' postdoctoral research in the Chemical Engineering Department at University of Wisconsin, Madison.



Dr. Lowe's research activities include design and development of multi-functional biomaterials for targeted and sustained drug and gene delivery, regenerative medicine, stem cell engineering, and biosensoring for the diagnoses and treatments of eye and brain diseases, diabetes, cancers, bone fractures, and cartilage damages, as well as contraception. She has published many high impact peer-reviewed papers in leading biomaterial related journals including Biomaterials, Tissue Engineering, and Advanced Drug Delivery Review, etc. She currently holds eight issued U.S. and international patents. She has lectured extensively in academia, industry, and throughout the global scientific community. Her research has been supported by NIH, DOD, Coulter Foundation, and JDRF, etc. Her research activities have been recognized in the RSC's Chemistry in Britain, Press Release of ARVO, and Feature Research in the "EURETINA-Brief" of European Association of Retina Specialists, etc.

Dr. Lowe has trained over 80 individuals who are/were postdocs, veterinary residents, and undergraduate, graduate, medical and pharmacy students, etc. She is a grant reviewer for over 90 study sections of NIH, NSF, DOD, EPA, USED, NSERC, ETHZ, etc. Dr. Lowe has serviced on the committees of a variety of professional societies including AAPS, BMES, SFB, ARVO, AIChE, ACS, and CRS, etc., and chaired over 35 sessions at international conferences. She was the Chair of the Biomaterials Area of American Institute of Chemical Engineers in 2010 and Past Chair/Co-Chair/Chair/Chair-Elect of the Nanotechnology Community of American Association of Pharmaceutical Scientists during 2014-2019. Dr. Lowe has achieved numerous honors and awards including Early Career Award in Translational Research from the Coulter Foundation.



Dr. Denis J. DiAngelo is a UTHSC Distinguished Professor of Biomechanics and Director of the BioRobotics and Rehabilitation Laboratory in the Department of Orthopaedic Surgery and Biomedical Engineering at UTHSC. His research has focused on the development of advanced robotic testing platforms that simulate how joints in the body move under different loading conditions. One such platform, the spine robot, was patented by UTRF and has been used to evaluate the biomechanics of the whole spinal system, including discs, ligaments, and muscles. This robot has opened opportunities for Dr. DiAngelo and his lab to do advanced testing and simulation with many medical device

companies where they have managed more than 80 independent sponsored industry projects and have evaluated more than 130 different medical devices.

More recently, his graduate students have used the robotic testing platform to design and validate new bracing technology, including a pediatric scoliosis brace, a dynamic ankle orthosis, and an offloading back support device. He has received two UTRF Maturation Fund grants to develop the ankle and back support technology, and has filed patent applications through UTRF on all three devices. During the summer of 2017, he participated with his graduate students in a local medical device accelerator program, Zero to 510, which led to the establishment of startup company EMBrace Design based around their unique offloading and mobility enabling spinal orthosis.

LICENSED TECHNOLOGIES CONTINUED

Duane Miller, Gabor Tigyi, Renuka Gupte, & Renukadevi Patil

Lawrence Pfeffer & Chuan Yang

Marko Radic

Startup Hwards

Wei Li

Kristen Archbold

Issued Patents

9,983,162 Method and Device for Detection of Bioavailable Drug Concentration

10,123,718

Methods, Systems, and Assemblies for Measuring Bioelectrical Signals of Intra-Abdominal Organs

10,155,728

Compounds for Treatment of Cancer

10,160,813

Tissue Plasminogen Activator Antibodies and Methods of Use

10,258,596

Method of Treating Her2-Positive Breast Cancers with Selective Androgen Receptor Modulators (SARMS) Benzyl and Naphthalene-Methyl Phosphonic Acid Inhibitors of Autotaxin with Anti-Invasive and Anti-Metastatic Actions

Licensee: Cayman Chemical

P65gst Fusion Protein Construct Licensee: Ximbio

Anti-Apoptosis Autoantibody and 3H9 Autoantibody

Licensee: Ximbio

Small Molecule MDM2 Degraders for Cancer Treatment Startup: SEAK Therapeutics, LLC

Maskless, Orally Retained, CPAP System with Nasal Pillows Startup: Azimuth Sleep Solutions, Inc.

Edward Chaum, Erno Lindner, & Jidong Guo

UTHSC College of Medicine, Department of Ophthalmology

Roger C. Young

UTHSC College of Medicine, Department of Obstetrics & Gynecology

Wei Li, Duane D. Miller, Yan Lu, & James T. Dalton

UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Guy Reed

UTHSC College of Medicine, Department of Medicine

Ramesh Narayanan, James T. Dalton, Mitchell S. Steiner, & Sunjoo Ahn

UTHSC College of Medicine, Department of Medicine-Hematology

ISSUED PATENTS CONTINUED

10,301,285

Compounds for Treatment of Cancer

10,314,771

Methods and Compositions for Preventing and Treating Tooth Erosion

10,314,797

Selective Androgen Receptor Degrader (SARD) Ligands and Methods of Use Thereof

10,314,807

Method of Treating Her2-Positive Breast Cancers with Selective Androgen Receptor Modulators (SARMS)

10,369,133

Immunosuppressive Compounds and Therapeutics

10,441,570

Selective Androgen Receptor Degrader (SARD) Ligands and Methods of Use Thereof

10,450,610

Single Nucelotide Polymorphisms (SNP) and Association with Resistance to Immune Tolerance Induction

10,470,993

Tooth Remineralization Compositions and Methods

Duane D. Miller, Wei Li, James T. Dalton, Jianjun Chen, Chien-Ming Li, & Sunjoo Ahn

UTHSC College of Medicine, Department of Medicine-Hematology & UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Mojdeh Dehghan, Daranee Versluis, & Hassan Almoazen

UTHSC College of Dentistry, Department of General Dentistry & UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy, Dong-Jin Hwang, & Yali He

UTHSC College of Medicine, Department of Medicine-Hematology & UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Ramesh Narayanan, James T. Dalton, Mitchell S. Steiner, & Sunjoo Ahn

UTHSC College of Medicine, Department of Medicine-Hematology

Duane Miller, Charles Ryan Yates, Jayaprakash Pagadala, Ram Mahato, & Hao Wu

UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Ramesh Narayanan, Duane Miller, Thamarai Ponnusamy, Dong-Jin Hwang, Yali He, Jayaprakash Pagadala, Charles Duke, Christopher Coss, & James T. Dalton

UTHSC College of Medicine, Department of Medicine-Hematology & UTHSC College of Pharmacy, Department of Pharmaceutical Sciences

Arnold E. Postlethwaite & Weikuan Gu

UTHSC College of Medicine, Department of Medicine-Rheumatology & Department of Orthopaedic Surgery

Liang Hong & Linfeng Wu

UTHSC College of Dentistry, Department of Community Dentistry

Keynote Speaker

Dr. Duane D. Miller is currently Professor Emeritus in the Department of Pharmaceutical Sciences at the University of Tennessee Health Science Center (UTHSC), Memphis, TN.

He obtained his BS degree in Pharmacy at Kansas University in 1966, and his interest in research was stimulated as a National Science Foundation Undergraduate Research Fellow. He was an NIH Fellow while at the University of Washington and obtained his PhD in Medicinal Chemistry in 1969. He next joined The Ohio State University Faculty in 1969, where he became Professor and Chairman of the Division of Medicinal Chemistry and Pharmacognosy in 1982.



He moved to the University of Tennessee Health Science Center, Memphis, TN, in 1992 and was the Van Vleet Endowed Chair and Professor. Dr. Miller has published over 430 publications, has 16 book chapters, has given 360 presentations at national and international meetings, and has over 400 patents and patent applications. Dr. Miller along with Dr. Jim Dalton discovered the first new nonsteroidal selective androgen receptor modulators (SARMs) and reported on them in 1998. His recent research has focused on discovery and development of new agents for unmet medical conditions such as resistant prostate cancer, inflammation, breast cancer, and advanced melanoma. He was inducted into the National Academy of Inventors in 2015 and is being honored at the 2019 UTRF Innovation Awards Ceremony for the receipt of his 100th U.S. patent.



Congratulations Dr. Miller!

Thank you!

UTRF Health Science Center FY 2019 Metrics



910 Madison Avenue, Suite 827 • Memphis, TN 38163 • 901-448-7827• utrf.tennessee.edu